Free Newsletter
Rabaxy hires Giuliani to lobby FDA
Ranbaxy Laboratories is calling in reinforcements--big-name reinforcements. The Indian generics maker has hired former New York mayor Rudy Giuliani to help it smooth relations with the FDA. Already thorny because of previous disputes over manufacturing safety, Ranbaxy's relationship with the agency worsened with Tuesday's ban on 30 Ranbaxy products.
What can Rudy do? His consulting firm's website says it specializes in helping companies "solve critical strategic issues." We'd say having virtually all of your drugs barred from a market that contributes over 20 percent of your sales is a "critical issue." But more to the point, Giuliani has represented another pharma firm in trouble with the government: He helped Purdue Pharma negotiate a settlement with prosecutors that kept execs out of jail.
Ranbaxy says retaining Giuliani should signal that the company is serious about working "cooperatively" with the FDA to get its drugs back on the market. Does this mean Ranbaxy is admitting to the manufacturing problems it denied before? We'll have to wait and see.
Ranbaxy's stock ended the day down 7 percent yesterday.
- check out Ranbaxy's response to the FDA
- view Ranbaxy's release regarding hiring Guiliani
- read the article from the BBC
Related Articles:
FDA halts Ranbaxy India imports
Ranbaxy investigation spins off new probes
Did FDA know Ranbaxy meds might be off?
Feds say Ranbaxy faked data
Ranbaxy probe includes AIDS relief meds
Comments
Giuliani just loves to work for convicted criminals. Speaks volumes for his integrity.
Even Rudy doesn't have enough lipstick for this pig.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: